This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

Prescient Therapeutics (ASX: PTX) said it has enrolled 20 evaluable patients in its Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma, the pre-specified threshold for the study’s first Dose Optimisation Committee review, according to a report published by Small Caps on September 18, 2026. The company said the review remains on track to convene in December 2026.

The study has two dosing arms with 10 evaluable patients in each, and a patient counts as evaluable on completing four treatment cycles, the report says. The committee, described as comprising clinical and biostatistical experts, is to review safety and efficacy data from both cohorts and give guidance on the continuation and design of further study development. The company said it will provide a market update after the committee’s recommendations, that the December review is a scheduled step within the trial rather than its completion, and that international enrolment continues toward a full target of 40 evaluable patients.

Chief executive James McDonnell said reaching the threshold reflected solid execution by the clinical team and trial sites. The report also restates the drug’s background: PTX-100 blocks the enzyme geranylgeranyl transferase-1, is described in company filings as the only inhibitor of that enzyme in clinical trials globally, showed what the company calls “positive efficacy and safety signals” in a Phase 1b expansion cohort in T-cell lymphomas, and holds US Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for relapsed or refractory mycosis fungoides.

GSN reviewed the Small Caps report rather than the ASX announcement itself. Small Caps’ standing disclaimer states that “There may be a conflict of interest present with commercial arrangements with companies and/or stock held”, and the report links to an investor briefing hosted by Reach Markets.

Reading the release

The announcement is an enrolment count, and it contains no result. Twenty evaluable patients, ten per arm, is half the 40 the study is targeting. The report gives no efficacy or safety figure for any of the 20, no number of patients enrolled but not yet evaluable, no number of sites or countries, and no date for reaching 40. The words “remains on track” commit the company to convening the committee in December; they say nothing about what it will find.

The two dosing arms are not described. The report does not give the dose levels, the schedule, or whether patients or investigators are blinded to arm, so a reader cannot judge what the committee is choosing between. Nor does it say what the committee’s options are: continue both arms, drop one, change the dose, or stop. The company says the review will guide “the continuation and design of further study development”, which covers all of those.

The committee is described by expertise, clinical and biostatistical, not by independence. The report does not say whether its members are independent of the company or of the trial sites, or who appoints them. The phrase used, “dose optimisation”, describes a body that chooses a dose, which is what a Phase 2a study is for; the company itself says the December review is not the end of the study.

Two parts of the story are repeats. The drug’s mechanism, its earlier Phase 1 and basket study results and its Orphan Drug and Fast Track designations were disclosed before; the report restates them as background, and the description of the Phase 1b cohort is the company’s characterisation of earlier data, not new data. The section of the Small Caps report headed “Commercial Significance”, which describes the review as a “value-inflection point” and speaks of de-risking, is the publisher’s commentary, not the company’s statement, and should be read as such.

The report gives no cash balance, no cost for completing enrolment to 40, and no timetable for the study’s end.

Questions worth asking

What are the two doses, and how were they chosen? The report describes two arms of ten evaluable patients each but gives no dose level or schedule, so the range the committee is optimising over is unknown.

How many patients have been enrolled in total, and how many dropped out before completing four cycles? Only evaluable patients are counted; the enrolled-to-evaluable ratio, which bears on tolerability, is not given.

Are the committee members independent of Prescient? The report describes them as clinical and biostatistical experts and says nothing about who appointed them or whether they have ties to the company or the sites.

What will the December market update contain? The company says it will report after the committee’s recommendations, but not whether it will publish the response and safety data the committee reviewed or only the recommendation.

Key terms in this story

Evaluable patient. A trial participant who has met the protocol’s condition for inclusion in an analysis, here completion of four treatment cycles. The count that triggered this announcement is of evaluable patients, so it is smaller than the number enrolled, which the report does not give.

Dose optimisation committee. A panel of clinicians and statisticians convened at a set point in a trial to compare the arms and advise on which dose to carry forward. The company’s committee meets for the first time in December, on the two arms of ten patients each.

Relapsed or refractory. A cancer that has come back after treatment or did not respond to it. The study enrols patients with cutaneous T-cell lymphoma in that position, and the Fast Track designation covers the same setting in the most common subtype, mycosis fungoides.

Orphan drug designation. A status the US regulator grants to a candidate for a rare disease, carrying development incentives and, if the drug is approved, a period of market exclusivity. The company holds it for all T-cell lymphomas; it is not an approval and does not bear on the December review.

What to watch

December 2026: the first Dose Optimisation Committee review, which the company said remains on track to convene.

After the review: the company said it will provide a market update following the committee’s recommendations; no date was given.

Sources